Trial: 201908080

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)



Principal Investigator

Hayashi, Robert

Disease Site

Lymphoid Leukemia; Non-Hodgkin Lymphoma

Learn more about this study at: